Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Short-term Investments (2017 - 2024)

Rein Therapeutics filings provide 8 years of Short-term Investments readings, the most recent being $25000.0 for Q3 2024.

  • For the quarter ending Q3 2024, Short-term Investments changed 0.0% year-over-year to $25000.0, compared with a TTM value of $25000.0 through Sep 2024, changed 0.0%, and an annual FY2023 reading of $25000.0, down 99.84% over the prior year.
  • Short-term Investments hit $25000.0 in Q3 2024 for Rein Therapeutics, roughly flat from $25000.0 in the prior quarter.
  • The five-year high for Short-term Investments was $44.6 million in Q3 2021, with the low at $25000.0 in Q2 2020.
  • Median Short-term Investments over the past 5 years was $25000.0 (2020), compared with a mean of $6.7 million.
  • The sharpest move saw Short-term Investments soared 122404.0% in 2022, then tumbled 99.92% in 2023.
  • Year by year, Short-term Investments stood at $6.8 million in 2020, then tumbled by 99.63% to $25000.0 in 2021, then soared by 64092.0% to $16.0 million in 2022, then tumbled by 99.84% to $25000.0 in 2023, then changed by 0.0% to $25000.0 in 2024.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $25000.0, $25000.0, and $25000.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.